Introduction {#Sec1}
============

Alcoholic liver disease (ALD) affects approximately 10 million people in the United States and is a significant economic burden and public health hazard^[@CR1]^. The pathogenesis of ALD stems from the production of toxic-reactive metabolites, reactive oxygen and nitrogen species (ROS and RNS), and oxidative stress associated with the metabolism of ethanol in hepatocytes^[@CR2]^. Fat accumulation in hepatocytes (steatosis) is the earliest histopathological change in the liver associated with alcohol intake^[@CR3]^. Continued steatosis results in hepatocyte death via apoptosis and necrosis which promotes inflammation and fibrosis formation^[@CR4],[@CR5]^. A large number of individuals who develop fatty liver suffer no further complications while others progress from steatosis to hepatitis (liver inflammation). Persistent hepatitis and hepatocyte death can result in scar formation in the liver (cirrhosis) resulting in impaired liver function and altered architecture^[@CR6]^. Persistent cirrhosis can ultimately lead to hepatocellular carcinoma and liver failure^[@CR7]^.

Macrophages are instrumental in promoting and resolving the hepatitis and fibrosis associated with ALD as evidenced by clinical observations that macrophage inflammatory genes are upregulated in ALD and cirrhosis patients^[@CR8]^. Furthermore, hepatic macrophage activation and enhanced production of tumor necrosis factor α (TNFα), interleukin (IL)-6, chemokine (C-C motif) ligand 2 (CCL2) and ROS is elicited with ethanol administration in ALD animals^[@CR9],[@CR10]^. Kupffer cells (KC), the liver resident macrophages, account for approximately 90% of the macrophage population in the healthy liver^[@CR11]^. KC are primarily involved in the maintenance of tissue homeostasis by serving as immune sentinels sensing pathogens, antigens or damaged cells through interactions with numerous cell surface receptors to initiate and potentiate the inflammatory response^[@CR12]^. The immune response to liver injury is initiated through the production of pro-inflammatory cytokines, IL-1β and TNFα by KC. Additionally, KC produce chemokines, such as CCL2, which induces the recruitment of additional inflammatory cells, such as monocytes, to the site of injury^[@CR13]^. Inflammation progresses with the chemotactic recruitment of Ly6C^+^ monocytes to inflamed tissue that differentiate into Ly6C^hi^ infiltrating macrophages (IMs)^[@CR13]^. During acute or chronic liver injury, the macrophage subtype promoting inflammation in the liver are Ly6C^hi^ monocyte-derived macrophages^[@CR14],[@CR15]^. Ly6C^hi^ macrophages exert pro-inflammatory, tissue-destructive responses as well as releasing pro-fibrotic mediators, such as IL-1β, platelet-derived growth factor (PDGF), connective tissue growth factor (CTGF) and transforming growth factor (TGF) β which activate hepatic stellate cells to deposit extracellular matrix and stimulate fibrosis formation^[@CR16]--[@CR19]^. While Ly6C^hi^ macrophages initially exert pro-fibrotic and pro-inflammatory function they can differentiate into Ly6C^low^ macrophages to facilitate tissue repair and inflammation resolution^[@CR20],[@CR21]^.

Macrophages represent an incredibly diverse cell type which, depending on tissue micro-environmental cues, switch from a pro- to anti-inflammatory phenotype in the progression of various diseases. The remarkable heterogeneity of macrophages is exemplified by their often opposing roles in a variety of diseases. For instance, pro-inflammatory macrophages are important in the elimination of extracellular pathogens, but are instrumental in the pathogenesis of atherosclerosis, autoimmune and metabolic diseases^[@CR22]^. Anti-inflammatory macrophages are instrumental in wound healing and inflammation resolution but when not properly regulated, factor into the pathogenesis of asthma, fibrosis and cancer development^[@CR23],[@CR24]^. During the progression of ALD, macrophages actively promote and resolve the inflammatory response, rendering therapeutic targeting of macrophages a significant challenge. Therefore, a thorough analysis of the metabolic and protein differences between Ly6C^hi^ and Ly6C^low^ infiltrating macrophages following ethanol consumption is imperative in understanding the signaling pathways governing macrophage phenotypic switching. This mechanism could be harnessed for targeted therapeutic manipulation of macrophage populations in the liver.

In the current study, we isolated Ly6C^hi^ and Ly6C^low^ macrophages from the livers of ethanol-fed mice and subjected the isolated cells to metabolomic and proteomic analysis to achieve an integrated bioinformatics approach. Here, we present an in-depth analysis of the altered metabolome and proteome between Ly6C^hi^ and Ly6C^low^ liver infiltrating macrophages following ethanol consumption. The data herein elucidates novel signaling mechanisms governing macrophage phenotypic switching, with the potential for opening new avenues for therapeutic targeting macrophage polarization in ameliorating ALD progression.

Results {#Sec2}
=======

Comparative Metabolomic Analysis of Ly6C^hi^ and Ly6C^low^ Infiltrating Macrophages Following Ethanol Administration {#Sec3}
--------------------------------------------------------------------------------------------------------------------

Infiltrating Ly6C^hi^ and Ly6C^low^ liver macrophage populations from ethanol fed mice were isolated by flow sorting (Fig. [1](#Fig1){ref-type="fig"}). Following macrophage isolation, metabolites were separated from proteins using cold methanol extraction. Following methyl-tert-butyl ether (MTBE) liquid-liquid extraction, metabolites were analyzed by mass spectrometry (Fig. [2](#Fig2){ref-type="fig"}). After performing statistical analysis of the peak height intensities in Mass Profiler Professional, the ANOVA significant metabolites were uploaded to Metaboanalyst. We identified a number of metabolites with significant fold change differences between the Ly6C^hi^ and Ly6C^low^ macrophages (Fig. [3](#Fig3){ref-type="fig"}). From the metabolite analysis, we observed 102 significantly altered metabolites between the macrophage subtypes (Table [1](#Tab1){ref-type="table"}). In the lipid positive fraction, we detected 58 differentially regulated metabolites with 39 upregulated and 19 downregulated in the Ly6C^low^ compared to the Ly6C^hi^ macrophages. From the lipid negative fraction, we measured 30 differentially regulated metabolites with 15 upregulated and 15 downregulated in the Ly6C^low^ compared to the Ly6C^hi^ macrophages. In the aqueous fraction, we detected 14 differentially regulated metabolites with 8 being upregulated and 6 downregulated in Ly6C^low^ compared to the Ly6C^hi^ macrophages. Following analysis with Metaboanalyst, we performed Metabolites Biological Role (MBROLE) analysis for pathway enrichment. From the 102 significantly altered metabolites we observed 6 pathways significantly enriched of which glycerophospholipid metabolism, arachidonic acid metabolism and phospholipid biosynthesis were further analyzed for their potential role in regulating macrophage polarization. (Table [2](#Tab2){ref-type="table"}). Ly6C^hi^ and Ly6C^low^ macrophages are significantly enriched for glycerophospholipid metabolism, metabolic pathways, arachidonic acid metabolism, linoleic metabolism and phospholipid biosynthesis with differential regulation of the metabolites involved in each functional pathway (Supplementary Table [S1](#MOESM1){ref-type="media"}).Figure 1Liver macrophage flow sorting schematic. CD45 was used to select for myeloid cells. CD11b and SiglecF were used to gate out eosinophils (Eos, CD11b^+^ SiglecF^+^) from macrophages (Mϕ, CD11b^+^ SiglecF^−^). Macrophages F4/80 and CD11b were used to identify infiltrating macrophages (IM, CD11b^hi^ F4/80^Int^) from Kupffer cells (KC, CD11b^Int^ F4/80^hi^). Mixture of V450 conjugated anti-Ly6G, CD3, CD19, NK1.1 were used to gated out the neutrophils, lymophocytes and Nature Killer cells. IM were finally separated into the two infiltrating macrophage phenotypes based on expression level of Ly6C: Ly6C^hi^ and Ly6C^low^.Figure 2Liver macrophage metabolomics and proteomics sample preparation.Figure 3Significantly alter metabolites between Ly6C^hi^ and Ly6C^low^ macrophages. (**A**) Log2 fold change of significantly altered metabolites (n = 3 in each experiment). The pink dots represent the significant metabolites. (**B**) Heat map of significantly altered metabolites (n = 3 in each experiment). Metabolites are significant with a fold change +/− 1.5 and t-test p \< 0.05 when comparing Ly6C^hi^ and Ly6C^low^.Table 1Significantly altered metabolites between Ly6C^hi^ and Ly6C^low^ macrophages.Compoundp(Low vs High)RegulationFold ChangeMassRetention TimeMetabolite ID**Lipid Positive Metabolites**17-Hydroxyprogesterone 1.14799991.92E-09Up52550.8330.22581.1480C01176MG(0:0/18:1/0:0)4.13E-07Up13307.73378.27482.5390C01885Prosafrinine0.01746852Up5.11865305.2340.7990LMSP01080051Cyclopassifloside V0.006721366Up4.075243882.44561.3970HMDB35947Okadaic acid0.005180489Up2.907953848.43171.4090C019455,8,11-Eicosatrienoic acid0.020084225Up2.815632306.25651.7910HMDB103785,8,11-Eicosatrienoic acid Esi + 1.79100020.03348608Up2.535191306.25541.7910HMDB10378Spectinomycin adenylate0.017278904Up2.418216683.19596.5740C03580CL(20:4/20:4/18:1/18:1)0.022371477Up2.3857731501.02815.2100C059809R-(2-cyclopentenyl)-1-nonanol 1.47500030.01784647Up2.252583232.17841.4750LMFA05000040CL(16:0/18:1/18:1/18:0)0.029356718Up2.2164481433.04355.2100C05980PA(18:3/18:3)0.044420037Up2.105103692.44873.3660LMGP10010015Resiniferatoxin0.001578898Up2.102412628.26971.4160C09179Narasin0.030150319Up2.018768786.50131.0990HMDB30448(R)-1-O-\[b-D-Glucopyranosyl-(1--6)-b-D-glucopyranoside\]-1,3-octanediol0.008763756Up1.982221470.24312.0950HMDB32799PI(16:1/0:0)0.0099774Up1.978465570.28011.3970LMGP06050009Mephentermine0.04304003Up1.732651163.13620.4740C078892-Hexyl-4,5-dimethyloxazole0.039262477Up1.682691181.14760.9940HMDB3789511H-14,15-EETA0.007826052Up1.674163358.20931.2530C148133-O-Benzyl-4,5-O-(1-methylethyldiene)-b-D-fructopyranose0.022699697Up1.646057310.13971.0070Lupinine0.015280782Up1.632106169.14930.9770C10773Perilloside C0.03297016Up1.615675338.17091.1480HMDB4056314,15-Epoxy-5,8,11-eicosatrienoic acid Esi + 1.15699980.03620125Up1.609097320.23281.1570C14771Vitamin A0.03911776Up1.604065286.22952.2710C004738,9,10,11-Tetrafluoro-8E,10E-dodecadien-1-ol0.02570673Up1.599283254.12930.9460LMFA050001682,2,11,13,15,16-hexachloro-docosane-1,14-disulfate0.03122542Up1.59914728.01545.2090LMFA00000019PG(14:0/16:0)0.047110956Up1.598646716.45133.0500LMGP0401002213-L-Hydroperoxylinoleic acid0.038854554Up1.579102312.22771.8080C047179R-(2-cyclopentenyl)-1-nonanol 6.9000010.03706475Up1.574036232.18296.9000LMFA05000040Decarbamoylneosaxitoxin0.039842825Up1.572547272.12430.4870HMDB33663Rubrobrassicin0.019814456Up1.565009757.21477.0090LMPK12010026Isovitexin 2″-O-(6‴-(E)-p-coumaroyl)glucoside0.021801876Up1.5623762.17337.0090LMPK12110271Linalyl oxide0.034410253Up1.521542170.13071.7150HMDB359071,8-Diazacyclotetradecane-2,9-dione0.039644323Up1.518688226.16850.4730C042773,4-Dihydrocadalene0.010371112Up1.512875200.15280.4720HMDB36453Camptothecin Esi + 1.4550.036810648Up1.457777370.09171.4550C01897Imiquimod0.04839949Up1.408694240.13451.1220HMDB14862Cycluron0.039257277Up1.328519220.15470.9920C191097″-O-Phosphohygromycin0.036477257Up1.277203629.18622.9640C03368Dodecanol0.04339384Down−1.38546208.18311.1930C02277Aristolochic Acid0.042970523Down−1.49828341.05211.1540C08469Ceramide (d18:1/22:0) 7.5010.01739148Down−1.61369621.60927.5010C00195Cer(d18:1/24:1)0.013293305Down−1.69156647.62247.4810C00195Cer(d18:0/24:1)0.026877573Down−1.70931649.6387.8760C001952-Hydroxydecanedioic acid0.003152832Down−1.9211240.09770.6050HMDB00424PE(20:1/20:3)0.035945572Down−1.95305795.57966.4140C00350N,N,O-Tridesmethyl-tramadol0.004404348Down−1.97113221.13980.8020HMDB60850Cer(d18:1/23:0)0.004459221Down−2.04499635.62117.6940C00195Ceramide (d18:1/20:0) 7.0630010.021412965Down−2.04623593.57577.0630C00195Alpha-CEHC Esi + 0.94400020.01759312Down−2.2515278.14960.9440HMDB01518Coenzyme Q90.03474693Down−2.26301794.62238.0660C01967Propofol glucuronide0.028436085Down−2.39699354.17361.2040HMDB60933Colnelenic acid0.00849326Down−2.50289292.20211.2090LMFA100000023E,7Z-Tetradecadienyl acetate0.02242055Down−2.81641252.20921.2060LMFA050003484-methyl-tridecanedioic acid0.017504424Down−2.98563258.18431.0030LMFA01170017MG(0:0/18:4/0:0) Esi + 1.4550.010899141Down−3.00273350.24181.4550C01885MG(0:0/18:4/0:0)0.015869742Down−3.90034350.24341.3730C0188524R-methylcholest-22E-en-3β,4β,5α,6α,8β,14α,15α,25 R,26-nonol1.38E-08Down−25218.3550.31251.3420LMST01031080**Lipid Negative Metabolites**Compoundp(Low vs High)RegulationFold ChangeMassRetention TimeMetabolite IDSeneciphylline1.58E-07Up13797.39333.1560.915C10391PC(20:3/P-18:1) 7.37000049.04E-09Up9632.273793.58857.3700004C00157PS(22:2/20:4)0.00619864Up2.130906863.56366.431C02737PE(20:1/20:3)0.008398175Up2.125419795.57656.4339986C00350PA(14:0/13:0)0.018941188Up2.03645614.36925.2680006C00416PE(20:2/P-18:1)0.004769958Up1.966516753.55747.0680003C00350PC(20:3/P-18:0)0.010843969Up1.91783795.60327.6989994C00157PE(14:0/22:1)0.02230334Up1.846544745.56945.279C00350PS(18:0/20:3)0.010184665Up1.82344813.55645.286C02737Ceramide (d18:1/22:0)0.024829699Up1.654491667.61067.5C00195Cer(d18:1/24:1)0.03071489Up1.651767693.62587.4820004C00195PE(24:0/P-16:0)0.020011874Up1.637358805.60887.485C00350PE(O-20:0/22:4)0.04190944Up1.518955809.61897.883001C13894PE(22:2/P-18:1)0.026633823Up1.515987781.58857.5039997C003501-(8-\[3\]-ladderane-octanoyl-2-(8-\[3\]-ladderane-octanyl)-sn-glycerol0.039579846Up1.211129650.51796.34LMGL02070009Ubiquinone-40.018471733Down−1.27887490.28432.4319997C00399PC(14:1/P-18:0)0.041162275Down−1.38207751.53575.2099996C00157Phytosulfokine b0.04650307Down−1.43648754.16181.097HMDB29810Rimocidine0.03588501Down−1.43716767.41123.0529997C15821Acetyl-N-formyl-5-methoxykynurenamine0.033569902Down−1.47063300.08851.156C05642alpha-Ribazole0.04385764Down−1.4749314.1041.2270001C05775Ceriporic acid A0.028160162Down−1.50262326.24531.656LMFA01170126PE(14:0/16:0)0.032299943Down−1.52035663.48335.243C00350CL(18:0/18:1/18:1/18:0)0.037032653Down−1.596661461.07086.4690013C05980CL(20:1/18:2/18:1/18:1)0.024215354Down−1.668821525.04925.209C05980PC(14:1/P-18:0) 5.3550.044275247Down−1.72501751.53515.355C00157LysoPE(0:0/22:5)0.049099866Down−1.78763509.28791.6539999C05973PE(14:1/20:4)0.009279267Down−1.84186709.46571.068C00350CL(18:0/18:0/18:2/18:0)0.03732978Down−2.061921457.0635.2099996C05980Camptothecin0.01822235Down−2.09969348.10680.9259999C01897**Aqueous Positive**PC(14:0/20:1)1.17E-06Up14552.3759.5772.7959998C00157LysoPE(0:0/20:4)4.39E-08Up8191.464501.28521.5950001C05973PE(18:2/18:2)8.68E-08Up6742.008739.51462.8740003C00350Ceramide(d18:1/17:0)0.033310328Up3.80966551.52720.8509999C00195Ceramide(d18:1/17:0) 0.847000060.030002557Up3.701004533.51650.8470001C00195CE(15:0)0.033051185Up2.817563609.58020.856C02530Hydroxybutyrylcarnitine0.049097747Up2.040182247.14335.395HMDB13127L-Carnitine0.037892483Up1.340674161.10525.8930006C00318Hydrocortisone caproate0.04131846Down−1.2559442.2720.7210001C134221,4′-Bipiperidine-1′-carboxylic acid0.00321868Down−1.31586211.1691.3240001C16836Methylconiine0.022564428Down−1.32673141.15081.441C10159Acetaminophen glucuronide 3.39800020.04299609Down−1.41856348.15223.3980002HMDB103164-Guanidinobutanoic acid0.006786303Down−1.45549145.0854.139C010355beta-Gonane0.008270364Down−2.18221254.19952.3449998C19640(n = 3 in each experiment). Metabolites were considered significant with a fold change +/− 1.5 and ANOVA p \< 0.05 when comparing Ly6C^hi^ and Ly6C^low^.Table 2MBROLE functional pathway enrichment of significantly altered metabolites between Ly6C^hi^ and Ly6C^low^ macrophages.MBROLE Pathway Enrichment AnalysisKEGG PathwayGlycerophospholipid metabolismp = 0.00000015RegulationFCMassRetention TimeMetabolite IDCompoundp (\[LOW\] vs \[HI\])HMDB07879PC(14:0/20:1)0.00000117Up14552.3759.5772.7959998C05973LysoPE(0:0/20:4)0.00000004Up8191.464501.28521.5950001C05980CL(20:4/20:4/18:1/18:1)0.02237148Up2.3857731501.0285.2099996C05980CL(16:0/18:1/18:1/18:0)0.02935672Up2.2164481433.0445.2099996C02737PS(22:2/20:4)0.00619864Up2.130906863.56366.431C00416PA(14:0/13:0)0.01894119Up2.03645614.36925.2680006C02737PS(18:0/20:3(8Z,11Z,14Z))0.01018467Up1.82344813.55645.286C05980CL(18:0/18:1/18:1/18:0)0.03703265Down−1.596661461.0716.4690013C05980CL(20:1/18:2/18:1/18:1)0.02421535Down−1.668821525.0495.209C05973LysoPE(0:0/22:5)0.04909987Down−1.78763509.28791.6539999C05980CL(18:0/18:0/18:2/18:0)0.03732978Down−2.061921457.0635.2099996HMDB09093PE(18:2/18:2)0.00000009Down−6742.01739.51462.8740003**HMDB PathwayArachidonic Acid Metabolismp = 0.025RegulationFCMassRetention TimeMetabolite IDCompoundp (\[LOW\] vs \[HI\])**C00157PC(14:0/20:1)1.17E-06Up14552.3759.5772.7959998C00157PC(20:3/P-18:1) 7.37000049.04E-09Up9632.273793.58857.3700004C00157PC(20:3/P-18:0)0.010843969Up1.91783795.60327.6989994HMDB0469311H-14,15-EETA0.007826052Up1.674163358.20931.2530001HMDB0426414,15-Epoxy-5,8,11-eicosatrienoic acid0.03620125Up1.609097320.23281.1569998C00157PC(14:1/P-18:0)0.041162275Down−1.38207751.53575.2099996C00157PC(14:1/P-18:0) 5.3550.044275247Down−1.72501751.53515.355**HMDB PathwayPhospholipid Biosynthesisp = 0.0000332RegulationFCMassRetention TimeMetabolite IDCompoundp (\[LOW\] vs \[HI\])**C00157PC(14:0/20:1)1.17E-06Up14552.3759.5772.7959998C00157PC(20:3/P-18:1) 7.37000049.04E-09Up9632.273793.58857.3700004C00350PE(18:2/18:2)8.68E-08Up6742.008739.51462.8740003C02737PS(22:2/20:4)0.00619864Up2.130906863.56366.431C00350PE(20:1/20:3)0.008398175Up2.125419795.57656.4339986C00350PE(20:1/20:3)0.008398175Up2.125419795.57656.4339986C00416PA(14:0/13:0)0.01894119Up2.03645614.36925.2680006C00350PE(20:2/P-18:1)0.004769958Up1.966516753.55747.0680003C00157PC(20:3/P-18:0)0.010843969Up1.91783795.60327.6989994C00350PE(14:0/22:1)0.02230334Up1.846544745.56945.279C02737PS(18:0/20:3)0.01018467Up1.82344813.55645.286C00350PE(24:0/P-16:0)0.020011874Up1.637358805.60887.485C00350PE(22:2/P-18:1)0.026633823Up1.515987781.58857.5039997C00157PC(14:1/P-18:0)0.041162275Down−1.38207751.53575.2099996C00350PE(14:0/16:0)0.032299943Down−1.52035663.48335.243C00157PC(14:1/P-18:0) 5.3550.044275247Down−1.72501751.53515.355C00350PE(14:1/20:4)0.009279267Down−1.84186709.46571.068(n = 3 in each experiment). Pathway enrichment was considered significantly with a MBROLE calculated p \< 0.05.

Comparative Proteomic Analysis of Ly6C^hi^ and Ly6C^low^ Infiltrating Macrophages Following Ethanol Administration {#Sec4}
------------------------------------------------------------------------------------------------------------------

Following methanol extraction of metabolites, the remaining protein pellet was subjected to protein extraction and tryptic digested for mass spectrometry proteomics analysis. Peptides detected by mass spectrometry were searched in Spectrum Mill to determine the protein identification. We detected 1,304 proteins in Ly6C^hi^ and Ly6C^low^ macrophages with 340 and 214 proteins, respectively, uniquely expressed between macrophage subtypes (Fig. [4A](#Fig4){ref-type="fig"}). The 1,304 protein found in the Ly6C^hi^ and Ly6C^low^ macrophages were subjected to DAVID analysis. From the 1,304 proteins analyzed, we observed 429 biological processes of which 105 were unique for Ly6C^low^ and 75 for Ly6C^high^ macrophages (Fig. [4B](#Fig4){ref-type="fig"}). Furthermore, we detected 200 molecular functions from the 1,304 proteins of which 23 are unique for Ly6C^low^ and 28 for Ly6C^high^ macrophages (Fig. [4C](#Fig4){ref-type="fig"}). The UniProt accession numbers for the common and unique proteins, biological processes and molecular functions are listed in the Supplementary Information Section (Supplementary Tables [S3](#MOESM1){ref-type="media"}--[S5](#MOESM1){ref-type="media"}). Protein quantitative analysis of significantly altered proteins was obtained from Mass Profiler Professional and we detected 47 differentially regulated proteins between the Ly6C^hi^ and Ly6C^low^ macrophages (Table [3](#Tab3){ref-type="table"}). The significantly altered proteins between the Ly6C^hi^ and Ly6C^low^ macrophages were analyzed using the DAVID bioinformatics resource and we observed a total of 21 biological processes and 9 molecular functions from DAVID analysis of the protein quantification obtained (Supplementary Table [S2](#MOESM1){ref-type="media"}). Of the significantly enriched biological processes and molecular functions, immune processes, actin polymerization and organization, phagocytosis, apoptotic processes and antigen presentation were selected for additional literature based analysis in their potential role for regulating macrophage polarization (Table [4](#Tab4){ref-type="table"}).Figure 4Venn Diagrams of unique protein, biological processes and molecular functions between Ly6C^hi^ and Ly6C^low^ macrophages. (**A**) Number of common and unique proteins between Ly6C^hi^ and Ly6C^low^ macrophages. (**B**) Number of common and unique biological processes between Ly6C^hi^ and Ly6C^low^ macrophages. (**C**) Number of common and unique molecular functions between Ly6C^hi^ and Ly6C^low^ macrophages. Lists of common and unique protein, biological processes and molecular functions can be found in Supplementary Tables [S3](#MOESM1){ref-type="media"}--[S5](#MOESM1){ref-type="media"}.Table 3Quantitative analysis of MS-only spectra of significantly altered proteins between Ly6C^hi^ and Ly6C^low^ macrophages.Quantitative Proteomics AnalysisProtein NameProtein IDPeptide \#p-valueFold Change (Low vs High)RegulationPhospholipase D3O3540528.24E-0932371.51UpCathepsin L1P0679742.77E-085875.09UpRas-related protein Rap-1bQ99JI624.55E-021512.80UpProtein S100-A9P3172584.06E-0532.22UpProtein S100-A8P2700552.17E-0431.14UpCathelin-related antimicrobial peptideP5143721.72E-0528.13UpH-2 class II histocompatibility antigen, A-B alpha chainP1443444.57E-0417.26UpH-2 class II histocompatibility antigen, A beta chainP1448341.85E-0415.85UpLactotransferrinP08071144.63E-0414.67UpNeutrophil gelatinase-associated lipocalinP1167222.42E-0314.47UpMacrophage asialoglycoprotein-binding protein 1P4930043.92E-046.48UpH-2 class II histocompatibility antigen gamma chainP0444147.13E-044.74UpCD177 antigenQ8R2S838.01E-044.70UpGelsolinP13020111.36E-033.17UpTranscription factor A, mitochondrialP4063029.01E-033.09UpVasodilator-stimulated phosphoproteinP7046021.67E-022.91UpEF-hand domain-containing protein D2Q9D8Y032.42E-022.79UpPutative phospholipase B-like 1Q8VCI069.23E-032.54UpChitinase-3-like protein 3O35744136.29E-032.54UpSynaptosomal-associated protein 23O0904424.40E-032.51UpLow affinity immunoglobulin gamma Fc region receptor IIP0810141.73E-022.46UpHistone H1.3P4327721.11E-022.33UpLymphocyte-specific protein 1P19973102.03E-022.15UpC-type lectin domain family 4 member FP70194125.30E-032.12UpAllograft inflammatory factor 1O7020035.35E-032.11UpAlpha-actinin-1Q7TPR4205.04E-032.08UpHematopoietic lineage cell-specific proteinP49710101.66E-022.02UpEF-hand domain-containing protein D1Q9D4J132.92E-022.02UpTyrosine-protein phosphatase non-receptor type substrate 1P9779724.56E-021.97UpHistone H1.0P1092221.22E-021.87UpAnnexin A1P10107141.22E-021.86UpIntegrin alpha-LP2406341.58E-021.74UpPrelamin-A/CP4867892.11E-021.52UpATP synthase subunit alpha, mitochondrialQ03265163.66E-021.49UpATP synthase subunit beta, mitochondrialP56480254.22E-021.43UpLysosome-associated membrane glycoprotein 1P1143834.39E-02−1.45DownFilamin-AQ8BTM8592.53E-02−1.57DownV-type proton ATPase subunit B, brain isoformP6281432.16E-02−1.79DownPlectinQ9QXS141.65E-02−1.80DownProliferation-associated protein 2G4P5058041.91E-02−1.85DownDNA-binding protein AQ9JKB323.33E-02−1.88DownGlutathione S-transferase Mu 1P1064982.57E-02−1.90DownTubulin alpha-4A chainP6836831.92E-02−1.98DownPolyadenylate-binding protein 1P2934156.88E-03−2.01DownIsocitrate dehydrogenase \[NADP\] cytoplasmicO8884444.32E-02−2.18DownLysozyme C-1P1789728.32E-03−2.27DownCoagulation factor XIII A chainQ8BH61136.73E-03−2.99Down(n = 3 in each experiment). Protein were considered significant with a Mass Protein Profiler calculated ANOVA p \< 0.05 when comparing Ly6C^hi^ and Ly6C^low^.Table 4DAVID functional pathway enrichment of significantly altered proteins between Ly6C^hi^ and Ly6C^low^ macrophages.Biological Processes Low vs HighGO IDTermCount%PValueFold Enrichment**GO:0019886Antigen Processing and Presentation of Exogenous Peptide Antigen via MHC Class II48.510.00001112.31Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P14434H-2 class II histocompatibility antigen, A-B alpha chain40.0004617.26UpP14483H-2 class II histocompatibility antigen, A beta chain40.0001915.85UpP04441H-2 class II histocompatibility antigen gamma chain40.000714.74UpP08101Low affinity immunoglobulin gamma Fc region receptor II40.017262.46Up**GO IDTermCount%PValueFold EnrichmentGO:0019882Antigen Processing and Presentation36.380.0079821.84Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P14434H-2 class II histocompatibility antigen, A-B alpha chain40.0004617.26UpP14483H-2 class II histocompatibility antigen, A beta chain40.0001915.85UpP04441H-2 class II histocompatibility antigen gamma chain40.000714.74Up**GO IDTermCount%PValueFold EnrichmentGO:0030041Actin Filament Polymerization36.380.0016149.14Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P13020Gelsolin110.001363.17UpO70200Allograft inflammatory factor 130.005352.11UpP49710Hematopoietic lineage cell-specific protein100.016582.02Up**GO IDTermCount%PValueFold EnrichmentGO:0031532Actin Cytoskeleton Reorganization36.380.0074222.68Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P31725Protein S100-A980.0000432.22UpP10107Annexin A1140.012231.86UpQ8BTM8Filamin-A590.02534−1.57Down**GO IDTermCount%PValueFold EnrichmentGO:0006911Phagocytosis, Engulfment48.510.0001934.94Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P13020Gelsolin110.001363.17UpP08101Low affinity immunoglobulin gamma Fc region receptor II40.017262.46UpO70200Allograft inflammatory factor 130.005352.11UpP97797Tyrosine-protein phosphatase non-receptor type substrate 120.045591.97Up**GO IDTermCount%PValueFold EnrichmentGO:0002376Immune System Process817.020.000048.21Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P31725Protein S100-A980.0000432.22UpP27005Protein S100-A850.0002231.14UpP14434H-2 class II histocompatibility antigen, A-B alpha chain40.0004617.26UpP14483H-2 class II histocompatibility antigen, A beta chain40.0001915.85UpP08071Lactotransferrin140.0004614.67UpP11672Neutrophil gelatinase-associated lipocalin20.0024214.47UpP04441H-2 class II histocompatibility antigen gamma chain40.000714.74UpP10107Annexin A1140.012231.86Up**GO IDTermCount%PValueFold EnrichmentGO:0006955Immune Response48.510.030035.78Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P14434H-2 class II histocompatibility antigen, A-B alpha chain40.0004617.26UpP14483H-2 class II histocompatibility antigen, A beta chain40.0001915.85UpP04441H-2 class II histocompatibility antigen gamma chain40.000714.74UpP08101Low affinity immunoglobulin gamma Fc region receptor II40.017262.46Up**GO IDTermCount%PValueFold EnrichmentGO:0006954Inflammatory Response510.640.010385.71Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P31725Protein S100-A980.0000432.22UpP27005Protein S100-A850.0002231.14UpO35744Chitinase-3-like protein 3130.006292.54UpO70200Allograft inflammatory factor 130.005352.11UpP10107Annexin A1140.012231.86Up**GO IDTermCount%PValueFold EnrichmentGO:0045087Innate Immune Response510.640.017224.91Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P31725Protein S100-A980.0000432.22UpP27005Protein S100-A850.0002231.14UpP51437Cathelin-related antimicrobial peptide20.0000228.13UpP11672Neutrophil gelatinase-associated lipocalin20.0024214.47UpP10107Annexin A1140.012231.86Up**GO IDTermCount%PValueFold EnrichmentGO:0043066Negative Regulation of Apoptotic process612.770.012864.17Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P08071Lactotransferrin140.0004614.67UpP04441H-2 class II histocompatibility antigen gamma chain40.000714.74UpO70200Allograft inflammatory factor 130.005352.11UpQ8BTM8Filamin-A590.02534−1.57DownP50580Proliferation-associated protein 2G440.01913−1.85DownQ9JKB3DNA-binding protein A20.03331−1.88Down**GO IDTermCount%PValueFold EnrichmentGO:0006915Apoptotic Process510.640.052693.45Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P31725Protein S100-A980.0000432.22UpP27005Protein S100-A850.0002231.14UpP11672Neutrophil gelatinase-associated lipocalin20.0024214.47UpP13020Gelsolin110.001363.17UpP19973Lymphocyte-specific protein 1100.020332.15Up**Molecular Functions Low vs HighGO IDTermCount%PValueFold EnrichmentGO:0003779Actin Binding817.020.000029.18Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P13020Gelsolin110.001363.17UpP70460Vasodilator-stimulated phosphoprotein20.016742.91UpP19973Lymphocyte-specific protein 1100.020332.15UpO70200Allograft inflammatory factor 130.005352.11UpQ7TPR4Alpha-actinin-1200.005042.08UpP49710Hematopoietic lineage cell-specific protein100.016582.02UpQ8BTM8Filamin-A590.02534−1.57DownQ9QXS1Plectin40.01647−1.80Down**GO IDTermCount%PValueFold EnrichmentGO:0051015Actin Filament Binding36.380.043718.81Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**O70200Allograft inflammatory factor 130.005352.11UpQ7TPR4Alpha-actinin-1200.005042.08UpQ8BTM8Filamin-A590.02534−1.57Down**GO IDTermCount%PValueFold EnrichmentGO:0005509Calcium Ion Binding919.150.000314.99Protein IDProtein NamePeptide \#p(Low vs High)Fold ChangeRegulation**P31725Protein S100-A980.0000432.22UpP27005Protein S100-A850.0002231.14UpP13020Gelsolin110.001363.17UpQ9D8Y0EF-hand domain-containing protein D230.024162.79UpO70200Allograft inflammatory factor 130.005352.11UpQ7TPR4Alpha-actinin-1200.005042.08UpQ9D4J1EF-hand domain-containing protein D130.029192.02UpP10107Annexin A1140.012231.86UpP56480ATP synthase subunit beta, mitochondrial250.042191.43Up(n = 3 in each experiment). Pathway enrichment was considered significant with a DAVID calculated t-test p \< 0.05 when comparing Ly6C^hi^ and Ly6C^low^.

Discussion {#Sec5}
==========

Alcoholic liver disease is a major public health issue and accounts for approximately 48% of liver cirrhosis related deaths^[@CR1]^. As infiltrating macrophages are known to mediate the pathogenesis of ALD from steatosis to cirrhosis^[@CR8]--[@CR10]^, analysis of the altered signaling pathways between the different subsets of these cells in response to ethanol is of the utmost importance in developing treatment options to prevent the progression of ALD or promote the reversal of scar tissue formation in the liver. Macrophages display a remarkable capacity to adapt their phenotype based on tissue micro-environmental cues such as lipid exposure, hypoxia, cytokines, and efferocytosis of apoptotic cells^[@CR21],[@CR25]^. To date, no studies have been conducted providing analysis of the cellular metabolome and proteome of infiltrating liver macrophages isolated from an *in vivo* model of ALD. While several studies have utilized immortalized mouse macrophages (RAW264.7) for transcriptomic^[@CR26]^ and lipidomic^[@CR26]--[@CR28]^ analysis following inflammatory stimuli, this study is the first to look at *in vivo* polarized macrophages in an ALD model, therefore allowing for the natural effects of the tissue microenvironment, such as the gut-liver signaling axis, and ethanol metabolism on regulating liver infiltrating macrophage phenotypes.

It has previously been shown that following phagocytosis of apoptotic hepatocytes, Ly6C^hi^ macrophages differentiate into Ly6C^low^ macrophages which express higher levels of phagocytosis related genes after alcohol intake^[@CR21]^. In healthy or control diet fed mouse livers, infiltrating macrophages are limited until liver insult elicits the recruitment of Ly6C^+^ monocytes into the liver tissue.^[@CR11],[@CR21],[@CR25]^ Therefore, the analysis done in this study was focused on the difference between Ly6C^hi^ and Ly6C^low^ macrophages from ethanol fed mice without comparison to control diet fed animals. In our present study, we observed a significant increase in phagocytosis and engulfment related proteins (Table [4](#Tab4){ref-type="table"}). We detected an upregulation of phagocytosis related proteins in Ly6C^low^ macrophages; this is expected as phagocytosis of apoptotic cells induces an anti-inflammatory phenotype^[@CR29],[@CR30]^. Additionally, we saw a significant enrichment in proteins involved in regulating the apoptotic process. Furthermore, we observed a significant enrichment in actin polymerization and cytoskeletal reorganization in Ly6C^low^ macrophages. Alterations in actin contractility, cytoskeletal organization and cellular elongation have been shown to induce macrophages to an anti-inflammatory phenotype as evidenced by increased arginase-1 and YM-1 expression, hallmarks of anti-inflammatory macrophage polarization^[@CR31]^. Additionally, defects in actin polymerization have been shown to attenuate macrophage phagocytic ability^[@CR32]^. This suggests further *in vivo* analysis of actin polymerization and cytoskeletal organization in murine macrophages may elucidate a novel therapeutic strategy in modulating macrophage phenotypes in ALD by affecting macrophage phagocytosis and response to apoptotic stimuli.

Recently Zhang *et al*. provided a comprehensive analysis profiling lipid species during *in vitro* differentiation of mouse and human macrophages cell lines. They reported a significant increase in the composition of glycerophospholipid species during macrophage differentiation. Furthermore, they saw a significant increase in the levels of lysophospholipids in anti-inflammatory macrophages compared to pro-inflammatory macrophages suggesting that modulation of glycerophospholipid metabolism could be a vital signaling component in differentiation of liver macrophage phenotypes^[@CR33]^. In our study, we found a significant enrichment in glycerophospholpid metabolism with differential metabolite regulation between Ly6C^hi^ and Ly6C^low^ macrophages. Additionally, we observed enrichment for arachidonic acid metabolism and phospholipid biosynthesis (Table [2](#Tab2){ref-type="table"}). In each of the enriched pathways, we detected a massive upregulation in multiple phosphatidylcholine (PC) species in Ly6C^low^ macrophages. PCs has been shown to promote an anti-inflammatory phenotype in macrophages through modulating actin assembly and increasing mycobacterium growth in RAW264.7 and J774 macrophages^[@CR34]^. Likewise, we observed a substantial upregulation in phosphatidylethanolamine (PE(18:2/18:2) in Ly6C^low^ macrophages. Following stimulation with nonsteroidal anti-inflammatory agents, macrophages have been shown to display an increase in multiple PE species and take on an anti-inflammatory phenotype^[@CR35]^. Therefore, the observed changes we see in PC and PE species correlate with *in vitro* studies highlighting the anti-inflammatory properties of PC and PE glycerophospholipid species in modulating macrophage phenotypes. Also of interest in regard to PE(18:2/18:2) is the linonleic acid (18:2) constituents present at the *sn-1* and *sn-2* positions, as linoleic acid has been shown to promote an anti-inflammatory phenotype in macrophages^[@CR36]^. These results suggest the involvement of phospholipase A~2~ (PLA~2~) in regulating macrophage polarization in ALD. PLA~2~ is involved in the hydrolysis of *sn*-2 fatty acids from membrane glycerophospholipids yielding a free fatty acid, arachidonic acid, and a lysophospholipid^[@CR37]^. The functions of PLA~2~ in modulating the inflammatory response have been well established in a variety of inflammatory contexts^[@CR38]--[@CR42]^. Ishihara *et al*. have shown that targeting cytosolic PLA~2~ activity in non-alcoholic fatty liver disease models proved beneficial in preventing hepatic fibrosis formation and reducing hepatocyte death^[@CR43],[@CR44]^. Rodrigues *et al*. showed that using diethylcarbmazine, which modulates arachidonic acid metabolism and cyclooxygenase-2 (COX-2) mediated prostaglandin production, elicited an anti-inflammatory and protective response in ALD^[@CR45]^. In addition to COX-2 mediated arachidonic acid metabolism and prostaglandin synthesis, arachidonic acid can be metabolized via cytochrome P450 epoxygenase mediated pathway to generate epoxyeicosatrienoic acids (EETs)^[@CR46]^. We found a significant increase in EETs in the Ly6C^low^ phenotype. Endogenous EETs have been shown to regulate the ability of *in vitro* THP-1 monocytes to differentiate into pro-inflammatory macrophages in response to pro-inflammatory stimuli (lipopolysaccharide (LPS) and interferon γ (IFNγ) as well as preventing differentiation under anti-inflammatory stimuli (IL-4)^[@CR46]^. Additionally, it has been shown that the immunomodulatory effect of EETs on inducing pro-inflammatory macrophage differentiation was facilitated through attenuation of NF-κB signaling^[@CR47]^. Finally, studies have shown that eicosatrienoic acid inhibits LPS induced inflammatory gene expression in macrophages^[@CR48]^. We detected an upregulation of eicosatrienoic acid metabolites in the anti-inflammatory, Ly6C^low^ macrophages after alcohol consumption. These studies coupled with the observed increase in arachidonic acid, glycerophospolipid metabolism and phospholipid biosynthesis as well as increased calcium ion binding suggest future investigation of the role of calcium dependent and independent PLA~2~ activity for therapeutic targeting of macrophage polarization in ALD.

The present study provides a framework for future studies utilizing multi-omics approaches for analyzing signaling difference between pro- and anti-inflammatory macrophages isolated from ALD mouse models. We detected a number of metabolic and protein mediated pathways that were significantly altered between the two macrophage subtypes, validating a number of *in vitro* studies analyzing the lipid, metabolite, and protein profile of polarized macrophages^[@CR26]--[@CR28],[@CR33],[@CR48]^. While the present study utilized an ALD model in which the degree of inflammation is not as evident histopathologically as more aggressive models, such as the NIAAA model, it allowed for the sufficient isolation of infiltrating liver macrophages not normally present in the healthy liver. We identified a number of metabolic pathways significantly altered due to the early onset of alcohol-induced hepatic inflammation (arachidonic acid metabolism, glycerophospholipid metabolism and phospholipid biosynthesis), which suggests that PLA~2~ enzymes play a critical role in modulating macrophage phenotypes. To explore the impact of PLA~2~ on ALD, future studies could utilize whole body PLA~2~ knockout mice or known PLA~2~ pharmacological inhibitors to elucidate the impact of PLA~2~ on macrophage polarization in ALD models. Overall, the data presented here justifies a further need to investigate numerous signaling mechanisms implicated in the modulation of macrophage phenotypes during ALD.

Materials and Methods {#Sec6}
=====================

Animal Model {#Sec7}
------------

Female C57BL/6 J mice (The Jackson Laboratory, Bar Harbor, ME, USA) (n = 30) were maintained under pathogen-free conditions in the Center for Laboratory Animal Care at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA). All experiments were performed using an Institutional Animal Care and Use Committee (IACUC) approved protocol and in accordance to the guidelines of the IACUC at the University of Colorado Anschutz Medical Campus. To elicit infiltrating macrophage recruitment to the liver, mice were fed an ethanol-containing Lieber-Decarli liquid diet (Bio-Serv, Flemington, NJ, USA). Ethanol content was introduced gradually by increasing 1.6% (v/v) every 2 days until 5%. All mice were then fed the liquid diet containing 5% ethanol for 4 weeks, as described previously^[@CR49],[@CR50]^.

Isolation of Liver Non-Parenchymal Cells (NPCs) {#Sec8}
-----------------------------------------------

Liver NPCs were isolated following a previously described method^[@CR51]^. Briefly, a 20-G catheter was put through the mouse superior vena cava, the inferior vena cava was clamped, and the portal vein cut. The liver was perfused with Hank's balanced salt solution (HBSS), followed by a digestion buffer \[1 × HBSS, supplemented with 0.04% collagenase (type IV; Sigma, St. Louis, MO, USA), 1.25 mM CaCl~2~, 4 mM MgSO~4~, and 10 mM HEPES\]. After digestion, the liver was disrupted in ACD solution (1 × HBSS, supplemented with 0.5% FBS, 0.6% citrate-dextrose solution, and 10 mM HEPES). Single cells were passed through a 100-μm cell strainer, and the cells were fractionated using 30% (w/v) Nycodenz (Axis-Shield PoC AS, Oslo, Norway) at 1.155 g/mL to yield liver NPCs and further purified using 30% Percoll (Sigma) at 1.04 g/mL.

Flow Cytometry Assisted Cell Sorting (FACS) {#Sec9}
-------------------------------------------

To purify KCs, Ly6C^hi^ and Ly6C^low^ IMs, liver NPCs were incubated with normal rat serum (Sigma) and anti-mouse FcγRII/III (Becton Dickinson, Franklin Lakes, NJ, USA) to minimize nonspecific antibody binding. Subsequently, the cells were stained with anti-CD45, anti-Ly6C, anti-Ly6G, anti-CD19, anti-SiglecF (Becton Dickinson) and anti-F4/80, anti-CD11b, anti-NK1.1 and anti-CD3 (eBioscience, San Diego, CA, USA), and sorted using a BD FACSAria II Cell Sorter (BD Bioscience, San Jose, CA, USA).

Metabolomics Sample Preparation and Analysis {#Sec10}
--------------------------------------------

Cell pellets from different sort dates were combined in order to get 3 technical replicates of approximately 400--500 K cells per sample type (Ly6C^hi^ and Ly6C^low^). Extractions were performed using volumes of 70% MeOH/water and 100% MeOH based on cell numbers. Cold methanol was used to precipitate proteins prior to liquid-liquid extraction of metabolites. Proteins pellets were saved for future proteomics analysis. Liquid-liquid extraction was performed on the supernatant using water and methyl tert-butyl ether (MTBE).The aqueous and lipid fractions were retained for analysis. Lipid fractions were analyzed using SB-C18 HPLC analytical column in positive and negative ionization mode on the Agilent 6560 IM-QTOF (in QTOF mode only). Aqueous fractions were analyzed using a HILIC column in positive ionization mode on the Agilent 6560 IM-QTOF (in QTOF mode only). A pooled sample was used as instrument QCs to monitor the entire instrument analysis. Initial data QC, peak threshold evaluation, retention time variation, and charge carrier evaluation was performed in Agilent MassHunter Qualitative Analysis, version B.07.00. Data extraction was performed in MassHunter Profinder, version B.08.00. Differential Analysis was performed in Agilent Mass Profiler Professional (MPP), version 14.5. Compound annotation (database searches and molecular formula generation) was performed in MassHunter ID Browser software, version 14.5. Raw MS data were checked for quality and reproducibility. Appropriate spectral and chromatogram peak height thresholds were determined by careful examination of the raw data. Appropriate charge carriers to be allowed during data extraction were determined after preliminary extraction on selected samples. The Agilent "recursive workflow" was used to prepare data. This workflow includes the following steps: 1) untargeted extraction using the Find-by-Molecular Feature algorithm, 2) mass and time alignment of extracted compounds, 3) targeted extraction using the Find-by-Ion algorithm (using the list of ions prepared in step 1), 4) final mass and time alignment of extracted compounds.

Metaboanalyst and Metabolites Biological Role (MBROLE) Analysis {#Sec11}
---------------------------------------------------------------

For Metaboanalyst comparison the following analysis parameters were used: Mass Tolerance: 0.05, No Missing Value Imputation, Data Filtering: Mean Intensity Value, Sample Normalization: Normalization by Sum, Data Transformation: None, Data Scaling: Mean Centering, Fold Change Threshold: 2, T-test: Group Variance Equal. For MBROLE metabolite functional enrichment analysis, pathways were considered significant with a p \< 0.05.

Proteomics Sample Preparation, nHPLC-MS and nHPLC-MS/MS Analysis {#Sec12}
----------------------------------------------------------------

Following methanol extraction for metabolomics, the remaining cell pellets from each technical replicate were processed using the PreOmics iST 8x Kit (Cat \# 00001) following the included protocol. Digested macrophage samples were loaded onto a 2 cm PepMAP 100, nanoviper trapping column and chromatographically resolved on-line using a 0.075 × 250 mm, 2.0 µm Acclaim PepMap RSLC reverse phase nano column (Thermo Scientific) using a 1290 Infinity II LC system equipped with a nanoadapter (Agilent). Mobile phases consisted of water + 0.1% formic acid (A) and 90% aq. acetonitrile + 0.1% formic acid (B). Samples were loaded onto the trapping column at 3.2 μL/min for 2.5 minutes at initial condition before being chromatographically separated at an effective flow rate of 345 nl/min using a gradient of 3--8.5% B over 4.0 minutes, 8.5--26% B over 48.5 minutes, and 26--35% over 7.5 minutes for a total 60 minute gradient. The gradient method was followed by a column wash at 70% B for 5 minutes. For nHPLC-MS, data was collected with a 6550 QTOF equipped with a nano source (Agilent) operated in MS mode. For nHPLC-MS/MS, data was collected with a 6550 QTOF equipped with a nano source (Agilent) operated using Data Dependent Acquisition CID Auto MS/MS. The capillary voltage, drying gas flow, and drying gas temperature were set to 1300 V, 11.0 l/min, and 200 C, respectively. Data was collected in positive ion polarity over mass ranges 290--1700 m/z at a scan rate of 1.5 spectra/s. MS/MS scans were collected over mass ranges 50--1700 m/z at a scan rate of 3 spectra/s. Singly charged species were excluded from being selected during MS/MS acquisition. Following data acquisition in MS/MS mode, sample data was searched in SpectrumMill to identify proteins.

DAVID Bioinformatics Analysis {#Sec13}
-----------------------------

Functional pathway enrichment of significantly altered proteins between Ly6C^hi^ and Ly6C^low^ macrophage population was analyzed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resource 6.8. For pathway enrichment, significantly altered proteins were compared to the whole mouse background. Pathways were considered significant with at least 3 proteins involved, a fold enrichment \>2, and a p \< 0.05.

Statistical Analysis {#Sec14}
--------------------

Statistical analysis of significantly altered metabolites and proteins was determined using Mass Profiler Professional Software. For Metaboanalyst, significantly altered metabolites were determined based of the difference in peak height intensity between the analyze metabolites with a p \< 0.05. For MBROLE analysis for metabolite functional pathway enrichment, pathways were considered significant with a p \< 0.05. For DAVID pathway enrichment, significantly altered proteins were compared to the whole mouse background. Pathways were considered significant with at least 3 proteins involved, a fold enrichment \>2, and a p \< 0.05.
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